Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
921 to 940 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy. | Biology (Basel) | 2022 | 35741415 | PubTator, text mining | PubMed |
| Comprehensive In Silico Analysis of Retrotransposon Insertions within the Survival Motor Neuron Genes Involved in Spinal Muscular Atrophy. | Biology (Basel) | 2022 | 35741345 | PubTator, text mining | PubMed |
| Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy. | Eur J Paediatr Neurol | 2022 | 35738181 | PubTator, text mining | PubMed |
| Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence. | Drug Des Devel Ther | 2022 | 35734367 | PubTator, text mining | PubMed |
| Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases. | Cell Mol Life Sci | 2022 | 35727341 | PubTator, text mining | PubMed |
| Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks. | Neurobiol Dis | 2022 | 35724821 | PubTator, text mining | PubMed |
| Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. | Nat Med | 2022 | 35715567 | PubTator, text mining | PubMed |
| Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. | Nat Med | 2022 | 35715566 | PubTator, text mining | PubMed |
| The Role of Ubiquitin in Regulating Stress Granule Dynamics. | Front Physiol | 2022 | 35694405 | PubTator, text mining | PubMed |
| Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy. | Cell | 2022 | 35688133 | PubTator, text mining | PubMed |
| Robust and accurate estimation of paralog-specific copy number for duplicated genes using whole-genome sequencing. | Nat Commun | 2022 | 35680869 | PubTator, text mining | PubMed |
| Using Next-Generation Sequencing and Bioinformatic Methods to Predict New Genes That May Be Regulated by CD47 in Oral Squamous Cell Carcinoma. | Curr Issues Mol Biol | 2022 | 35678681 | PubTator, text mining | PubMed |
| Effects of Inhibitors of SLC9A-Type Sodium-Proton Exchangers on Survival Motor Neuron 2 (SMN2) mRNA Splicing and Expression. | Mol Pharmacol | 2022 | 35667685 | PubTator, text mining | PubMed |
| Critical Reflections on Reimbursement and Access of Advanced Therapies. | Front Pharmacol | 2022 | 35662719 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Spinal Muscular Atrophy: SMN1 Copy Number, Intragenic Mutation, and 2 + 0 Carrier Analysis by Third-Generation Sequencing. | J Mol Diagn | 2022 | 35659528 | PubTator, text mining | PubMed |
| Therapeutic Decision-Making Under Uncertainty in the Management of Spinal Muscular Atrophy: Results From DECISIONS-SMA Study. | Neurol Ther | 2022 | 35657490 | PubTator, text mining | PubMed |
| Commentary: Current Status of Gene Therapy for Spinal Muscular Atrophy. | Front Cell Neurosci | 2022 | 35656408 | PubTator, text mining | PubMed |
| fingeRNAt-A novel tool for high-throughput analysis of nucleic acid-ligand interactions. | PLoS Comput Biol | 2022 | 35653385 | PubTator, text mining | PubMed |
| Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus-response in spinal muscular atrophy. | Transl Neurodegener | 2022 | 35650592 | PubTator, text mining | PubMed |
| Splicing mutations in the CFTR gene as therapeutic targets. | Gene Ther | 2022 | 35650428 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=47